Developer docs
API playgroundTry for free, no card

Search company profiles

Navinci Diagnostics

Full company profile

uuid0000j1g

Namestring
Navinci Diagnostics
Legal namestring
Navinci Diagnostics AB
Websiteurl
navinci.se
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Navinci Diagnostics AB is a privately held Swedish biotech company headquartered in Uppsala that develops proprietary in situ proximity ligation assay (isPLA) kits and reagents under the Naveni® brand for spatial proteomics research. The company's technology uses antibody-oligonucleotide conjugates (Navenibodies) that generate amplifiable DNA signals only when two target proteins are in close proximity, enabling detection of protein-protein interactions, post-translational modifications, and single protein localization directly in cultured cells, fresh-frozen tissue, and FFPE samples while preserving native spatial context — a capability that traditional methods such as co-immunoprecipitation and Western blot cannot provide. Its product portfolio spans flexible kits (NaveniFlex, NaveniBright) usable with researchers' own primary antibodies, target-specific kits (PD1/PD-L1, CD8/MHC-I), the NaveniPlex 3-plex platform, BOND RX/RXm-automated kits for high-throughput workflows, the recently launched Omni 9-plex kit, and the Glysite Explorer co-developed with Vector Laboratories for protein glycosylation research.

Navinci sells its products primarily through a direct e-commerce storefront (order.navinci.se) with an Omni Panel Builder for custom configurations, complemented by an international distributor network and CRO Service Partners; the company also offers a full-service laboratory option for researchers who prefer outsourced experimentation. Pricing is published in Swedish Krona and ranges from approximately SEK 3,500 for control kits to SEK 29,500 for automated BOND RX kits, with custom Omni panels quoted on a per-project basis, generating one-time-purchase consumable revenue plus service-based revenue. The customer base is global across EMEA, North America, and Asia Pacific, consisting primarily of academic and translational life science researchers, immuno-oncology investigators, pharmaceutical/biotech drug discovery teams, and academic core facilities such as SciLifeLab; named adopters include Harvard Medical School, Providence Genomics, IFOM, and the University of Palermo.

The company was founded in 2004 and remains privately held, having closed a SEK 90 million Series A in July 2022 led by Segulah Medical Acceleration. In FY2025 Navinci reported sales revenue of SEK 18.1m (up 72% year-over-year, or 86% on a constant-currency basis) with a gross margin of approximately 74.6% and a still-significant EBIT loss of SEK -37.4m, as the business invests in commercial scaling under a newly completed management team and the April 2026 launch of its Omni multiplex platform.

Short descriptiontext

Navinci Diagnostics is a Swedish biotech company developing proprietary in situ proximity ligation assay (isPLA) kits for spatial proteomics. It sells Naveni® reagent kits and the Omni multiplex platform to academic researchers, immuno-oncology investigators, and pharmaceutical drug-discovery teams worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial proteomics reagents, proximity ligation assays, protein interaction detection, research reagent kits, tissue-based assays
Industry2 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Spatial Proteomics Reagents
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Research kits and reagents
TypeOne Time License
Description

Navinci sells proprietary in situ proximity ligation assay kits including flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), and multiplex platforms (Naveni Plex, Omni). Products are sold directly and through distributors globally. Prices range from approximately 3,500 SEK to 29,500 SEK for standard kits, with custom Omni panels quote-based.

navinci.se
2Custom service offerings
TypeProfessional Services
Description

Omni is available as both a ready-to-use kit for in-house experiments and a full-service offering performed by Navinci experts, providing service-based revenue alongside product sales.

navinci.se
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details9 tiers
1Naveni Detect + Interact kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

22,500 SEK - Flexible in situ kit for detecting protein-protein interactions with mouse and rabbit primary antibodies

navinci.se
2NaveniBright PD1/PD-L1 BOND RX HRP kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

29,500 SEK - Automated assay kit for BOND RX/RXm for PD1/PD-L1 interaction detection with chromogenic readout

navinci.se
3Naveni PD1/PD-L1 Atto647N kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

24,500 SEK - Fluorescent assay kit for PD1/PD-L1 interaction detection with Atto647N fluorophore

navinci.se
4NaveniBright kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

18,500 SEK - Chromogenic detection kit for proteins, protein-protein interactions, or modifications

navinci.se
5NaveniFlex Tissue Red kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

16,500 SEK - Tissue-optimized kit with TEX615 fluorophore for protein interactions/modifications

navinci.se
6NaveniFlex Cell Red kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

16,000 SEK - Cell-optimized kit with TEX615 fluorophore for protein interactions/modifications

navinci.se
7Naveni Control Kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

3,500 SEK - Control kit for validating proximity ligation assay signals with NaveniFlex/NaveniBright

navinci.se
8NaveniLink kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

11,500 SEK - Conjugation kit for creating custom Navenibodies with user-provided primary antibodies

navinci.se
9Omni multiplex kit (custom)
ModelOtherBilling cadencePay-as-you-go
Notes

Custom pricing via Omni Panel Builder - Up to 9-plex simultaneous detection; available as ready-to-use kit or full-service offering

navinci.se
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Naveni®
Description

Proprietary in situ proximity ligation assay technology platform and product line including NaveniFlex, NaveniBright, NaveniPlex, and related kits

navinci.se
+7 more records
Core offering1 text field

Navinci develops and commercializes proprietary in situ proximity ligation assay (isPLA) reagent kits for detecting proteins, protein-protein interactions, and post-translational modifications directly within tissue and cell samples, preserving spatial context. The product portfolio includes flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), multiplex kits (Naveni Plex, Omni), and glycosylation detection kits (Glysite Explorer), sold to life science researchers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 72% year-over-year sales growth in 2025 (86% adjusted for currency)
+2 more records
Product and service12 records
1NaveniFlex kits
CategoryFlexible proximity ligation assay kits
Description

Flexible in situ proximity ligation assay kits that allow researchers to use one or two of their own primary IgG antibodies combined with Navenibodies for secondary detection. Available in cell and tissue formats with fluorescent readouts (Atto647N, Red/TEX615) for proteins, protein-protein interactions, or modifications in cultured cells, fresh-frozen, and FFPE samples. Prices range from 16,000 to 16,500 SEK.

2NaveniBright kits
CategoryChromogenic proximity ligation assay kits
Description

Chromogenic in situ proximity ligation assay detection kits using HRP substrate for visualization of proteins, protein-protein interactions, or modifications. Priced at 18,500 SEK, suitable for use with standard brightfield microscopy workflows on FFPE, fresh-frozen, and cultured cell samples.

3Naveni Plex
CategoryMultiplex proximity ligation assay kits
Description

First multiplex in situ proximity ligation assay with fluorescent readout, enabling simultaneous detection of 3 separate targets or protein-protein interactions with enhanced specificity and sensitivity. Validated on FFPE human tissue samples with combinations such as PD1/PD-L1, PD1/PD-L2, PD1/SHP-2, CD8/MHC-I, and CD3.

4Omni multiplex kit
CategoryMultiplex spatial interactomics kits
Description

Next-generation multiplex in situ proximity ligation assay enabling simultaneous detection of up to 9 protein-protein interactions, post-translational modifications, or single protein targets in a single experiment with fluorescent readout. Built on proprietary isPLA technology and available as a ready-to-use customized kit or as a full-service offering performed by Navinci experts. Configured through the Omni Panel Builder with quote-based pricing.

5Glysite Explorer
CategoryGlycosylation detection kits
Description

First commercially available kit to study protein glycosylation with spatial context, integrating Vector Laboratories' Glysite Explorer lectins with Navinci's proprietary in situ proximity ligation assay technology. Detects glycans proximal to proteins in tissue samples. Jointly developed with Vector Laboratories and recognized with the CiteAb Innovation Award (Highly Commended) in 2026.

6Naveni Detect + Interact (NaveniTriFlex)
CategoryTriFlex protein detection and interaction kits
Description

Proximity-based in situ kit that concurrently visualizes two proteins in free and complex state using three-channel fluorescent readout, detecting total protein A, total protein B, and interaction AB simultaneously. Priced at 22,500 SEK for use with mouse and rabbit primary antibodies to study functional states and protein interplay.

7Naveni PD1/PD-L1 target-specific kits
CategoryTarget-specific immuno-oncology kits
Description

Target-specific kits for detecting PD1/PD-L1 interactions in situ with high signal-to-noise ratio. Available in NaveniBright chromogenic (HRP), Atto647N fluorescent, and BOND RX automated versions. First commercial assay for detecting PD1/PD-L1 interaction in situ, used in immunotherapy research and patient stratification studies. Prices range from 18,500 to 29,500 SEK.

8Naveni CD8/MHC-I kit
CategoryTarget-specific immuno-oncology kits
Description

Target-specific in situ proximity ligation assay kit for detecting CD8/MHC-I interactions, offering novel insights into T-cell engagement and antigen recognition for immune cell dynamics research. Used by Providence Genomics and academic researchers in immunology and immuno-oncology.

9Naveni BOND RX automated kits
CategoryAutomated staining kits
Description

Automated proximity ligation assay kits optimized for the Leica BOND RX and RXm Fully Automated Research Stainer, with pre-optimized protocols enabling high-throughput processing. Includes chromogenic (NaveniBright HRP, 29,500 SEK for PD1/PD-L1) and other readout formats designed for immediate application on BOND RX/RXm instruments.

10Naveni Control Kit
CategoryAssay validation reagents
Description

Control kit used for validating proximity ligation assay signals when running NaveniFlex and NaveniBright kits. Priced at 3,500 SEK.

11NaveniLink kit
CategoryAntibody conjugation reagents
Description

Conjugation kit for creating custom Navenibodies (antibody-oligonucleotide conjugates) with user-provided primary antibodies. Priced at 11,500 SEK, enables researchers to expand the isPLA platform to additional targets of interest.

12Omni full-service offering
CategoryCustom assay services
Description

Full-service offering for the Omni multiplex kit where Navinci experts perform the experiment on behalf of the customer. Enables researchers without in-house capability to access multiplex spatial interactomics experiments performed by Navinci's scientific team.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Collaboration as part of the SIXP (Spatial Interactomics with Cell Painting) project to develop next-generation technology platform for mapping cellular signaling and drug responses. Uppsala contributes leading expertise in molecular interaction biology and drug discovery. Joint work includes proof-of-concept studies for Omni technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Collaboration in the SIXP project providing advanced high content imaging, screening capabilities and data infrastructure. Once established, technology will be implemented within CBCS infrastructure at SciLifeLab enabling national research access.

3Chemical Biology Consortium Sweden (CBCS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Part of SIXP collaboration; provides screening infrastructure and will host the technology platform for researcher access across Sweden supporting drug discovery, systems biology, and precision medicine applications.

navinci.se
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-04-07
Description

Provides advanced image analysis and AI-based tools for spatial data interpretation as part of the SIXP collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Joint development of Glysite Explorer kit, integrating Vector's Glysite Explorer lectins with Navinci's proprietary in situ PLA technology for studying protein glycosylation. Won CiteAb Innovation Award 2026. Product adopted by leading research institutions worldwide.

Strategic tierSupportingTypeTechnology or Integration
Description

BOND RX/RXm compatibility - Navinci has developed automated proximity ligation assay kits optimized for Leica BOND RX/RXm Fully Automated Research Stainer, enabling high-throughput processing.

7Harvard Medical School (Barthel and Schatton laboratories)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaborative research using Glysite Explorer for studying protein glycosylation in tumor microenvironment; presented findings at NextGen Omics and AACR 2026 conferences.

navinci.se
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Rebus Biosystems
TypeEmerging player
Description

Emerging U.S. spatial omics company with the STELLARIS platform for highly multiplexed spatial transcriptomics. Competes in the same translational research market but with a narrower technology scope focused on RNA rather than protein-protein interactions.

TypeOthers
Description

Large U.S. life sciences reagents company (including R&D Systems, ProteinSimple, and Advanced Cell Diagnostics) selling antibodies, ELISA kits, and spatial biology reagents. Indirectly comparable as a broad proteomics reagent supplier that researchers may substitute or bundle against Navenci's specialty kits.

TypeBroad incumbent
Description

Former Fluidigm; commercializes the Hyperion imaging mass cytometry platform for highly multiplexed spatial proteomics in tissue. Competes for spatial-proteomics core facility budgets with a broader, more capital-intensive instrument-based offering.

TypeDirect peer
Description

Swedish protein biomarker company using Proximity Extension Assay (PEA), a dual-recognition proximity-based technology closely analogous to Navinci's isPLA. Most directly comparable peer by origin (Sweden/Uppsala) and underlying proximity-detection chemistry, though Olink operates in soluble protein biomarkers rather than in situ tissue.

TypeBroad incumbent
Description

U.S. leader in single-cell and spatial biology with the Xenium in situ platform (RNA plus emerging protein assays), Visium, and Chromium product lines. Overlaps with Navinci in spatial tissue analysis but addresses a much broader multi-omics portfolio with substantially larger commercial reach.

TypeDirect peer
Description

Swiss spatial biology company commercializing the COMET multiplex sequential immunofluorescence platform for tissue proteomics. Directly comparable to Navinci's NaveniFlex/NaveniBright and Omni kits as a competing approach to high-multiplex spatial protein detection in FFPE tissue.

TypeDirect peer
Description

U.S. spatial biology company offering the PhenoCycler (formerly CODEX) platform and OPAL multiplex immunohistochemistry reagents for tissue-based multiplex proteomics. Competes with Navinci for the same translational and academic research budget for spatial protein analysis in tissue.

TypeDirect peer
Description

Major U.S. antibody and reagent supplier that also markets proximity ligation assay (PLA) kits and IHC reagents. Directly competes with Naveni product lines at the bench-reagent level while also offering the broader antibody portfolio and assay support that researchers often consolidate on.

TypeOthers
Description

U.S. immunohistochemistry reagent supplier and Navinci's co-development partner on Glysite Explorer. Adjacent rather than competitive — provides lectin reagents and IHC consumables that Navinci integrates into its isPLA kits.

TypeBroad incumbent
Description

Spatial biology platforms including CosMx SMI (single-cell spatial molecular imaging) and GeoMx DSP for digital spatial profiling. Larger incumbent with broader spatial transcriptomics and proteomics coverage than Navinci's protein-interaction focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Navinci Diagnostics

Spatial Proteomics Reagentsnavinci.se

Navinci Diagnostics is a Swedish biotech company developing proprietary in situ proximity ligation assay (isPLA) kits for spatial proteomics. It sells Naveni® reagent kits and the Omni multiplex platform to academic researchers, immuno-oncology investigators, and pharmaceutical drug-discovery teams worldwide.

What Navinci Diagnostics does

Navinci Diagnostics AB is a privately held Swedish biotech company headquartered in Uppsala that develops proprietary in situ proximity ligation assay (isPLA) kits and reagents under the Naveni® brand for spatial proteomics research. The company's technology uses antibody-oligonucleotide conjugates (Navenibodies) that generate amplifiable DNA signals only when two target proteins are in close proximity, enabling detection of protein-protein interactions, post-translational modifications, and single protein localization directly in cultured cells, fresh-frozen tissue, and FFPE samples while preserving native spatial context — a capability that traditional methods such as co-immunoprecipitation and Western blot cannot provide. Its product portfolio spans flexible kits (NaveniFlex, NaveniBright) usable with researchers' own primary antibodies, target-specific kits (PD1/PD-L1, CD8/MHC-I), the NaveniPlex 3-plex platform, BOND RX/RXm-automated kits for high-throughput workflows, the recently launched Omni 9-plex kit, and the Glysite Explorer co-developed with Vector Laboratories for protein glycosylation research.

Navinci sells its products primarily through a direct e-commerce storefront (order.navinci.se) with an Omni Panel Builder for custom configurations, complemented by an international distributor network and CRO Service Partners; the company also offers a full-service laboratory option for researchers who prefer outsourced experimentation. Pricing is published in Swedish Krona and ranges from approximately SEK 3,500 for control kits to SEK 29,500 for automated BOND RX kits, with custom Omni panels quoted on a per-project basis, generating one-time-purchase consumable revenue plus service-based revenue. The customer base is global across EMEA, North America, and Asia Pacific, consisting primarily of academic and translational life science researchers, immuno-oncology investigators, pharmaceutical/biotech drug discovery teams, and academic core facilities such as SciLifeLab; named adopters include Harvard Medical School, Providence Genomics, IFOM, and the University of Palermo.

The company was founded in 2004 and remains privately held, having closed a SEK 90 million Series A in July 2022 led by Segulah Medical Acceleration. In FY2025 Navinci reported sales revenue of SEK 18.1m (up 72% year-over-year, or 86% on a constant-currency basis) with a gross margin of approximately 74.6% and a still-significant EBIT loss of SEK -37.4m, as the business invests in commercial scaling under a newly completed management team and the April 2026 launch of its Omni multiplex platform.

Navinci Diagnostics firmographics

Firmographics
Name
Navinci Diagnostics
Legal name
Navinci Diagnostics AB
Website
https://navinci.se
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Navinci Diagnostics is a Swedish biotech company developing proprietary in situ proximity ligation assay (isPLA) kits for spatial proteomics. It sells Naveni® reagent kits and the Omni multiplex platform to academic researchers, immuno-oncology investigators, and pharmaceutical drug-discovery teams worldwide.
Ownership category
akta.pro rank

Navinci Diagnostics industry classification

Industry
Product category
Spatial Proteomics Reagents
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Spatial proteomics reagents
  • Proximity ligation assays
  • Protein interaction detection
  • Research reagent kits
  • Tissue-based assays

Where Navinci Diagnostics is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Navinci Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Research kits and reagents: Navinci sells proprietary in situ proximity ligation assay kits including flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), and multiplex platforms (Naveni Plex, Omni). Products are sold directly and through distributors globally. Prices range from approximately 3,500 SEK to 29,500 SEK for standard kits, with custom Omni panels quote-based.
  2. Custom service offerings: Omni is available as both a ready-to-use kit for in-house experiments and a full-service offering performed by Navinci experts, providing service-based revenue alongside product sales.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNaveni Detect + Interact kit
Unit PricingPay-as-you-goNaveniBright PD1/PD-L1 BOND RX HRP kit
Unit PricingPay-as-you-goNaveni PD1/PD-L1 Atto647N kit
Unit PricingPay-as-you-goNaveniBright kit
Unit PricingPay-as-you-goNaveniFlex Tissue Red kit
Unit PricingPay-as-you-goNaveniFlex Cell Red kit
Unit PricingPay-as-you-goNaveni Control Kit
Unit PricingPay-as-you-goNaveniLink kit
OtherPay-as-you-goOmni multiplex kit (custom)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Navinci Diagnostics product offering

Product offering

Core offering

Navinci develops and commercializes proprietary in situ proximity ligation assay (isPLA) reagent kits for detecting proteins, protein-protein interactions, and post-translational modifications directly within tissue and cell samples, preserving spatial context. The product portfolio includes flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), multiplex kits (Naveni Plex, Omni), and glycosylation detection kits (Glysite Explorer), sold to life science researchers globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Naveni®: Proprietary in situ proximity ligation assay technology platform and product line including NaveniFlex, NaveniBright, NaveniPlex, and related kits
  • Omni
  • NaveniFlex
  • NaveniBright
  • NaveniPlex
  • Glysite™ Explorer
  • NaveniTriFlex
  • NaveniDetect

Products and services

  • NaveniFlex kits Flexible in situ proximity ligation assay kits that allow researchers to use one or two of their own primary IgG antibodies combined with Navenibodies for secondary detection. Available in cell and tissue formats with fluorescent readouts (Atto647N, Red/TEX615) for proteins, protein-protein interactions, or modifications in cultured cells, fresh-frozen, and FFPE samples. Prices range from 16,000 to 16,500 SEK.
  • NaveniBright kits Chromogenic in situ proximity ligation assay detection kits using HRP substrate for visualization of proteins, protein-protein interactions, or modifications. Priced at 18,500 SEK, suitable for use with standard brightfield microscopy workflows on FFPE, fresh-frozen, and cultured cell samples.
  • Naveni Plex First multiplex in situ proximity ligation assay with fluorescent readout, enabling simultaneous detection of 3 separate targets or protein-protein interactions with enhanced specificity and sensitivity. Validated on FFPE human tissue samples with combinations such as PD1/PD-L1, PD1/PD-L2, PD1/SHP-2, CD8/MHC-I, and CD3.
  • Omni multiplex kit Next-generation multiplex in situ proximity ligation assay enabling simultaneous detection of up to 9 protein-protein interactions, post-translational modifications, or single protein targets in a single experiment with fluorescent readout. Built on proprietary isPLA technology and available as a ready-to-use customized kit or as a full-service offering performed by Navinci experts. Configured through the Omni Panel Builder with quote-based pricing.
  • Glysite Explorer First commercially available kit to study protein glycosylation with spatial context, integrating Vector Laboratories' Glysite Explorer lectins with Navinci's proprietary in situ proximity ligation assay technology. Detects glycans proximal to proteins in tissue samples. Jointly developed with Vector Laboratories and recognized with the CiteAb Innovation Award (Highly Commended) in 2026.
  • Naveni Detect + Interact (NaveniTriFlex) Proximity-based in situ kit that concurrently visualizes two proteins in free and complex state using three-channel fluorescent readout, detecting total protein A, total protein B, and interaction AB simultaneously. Priced at 22,500 SEK for use with mouse and rabbit primary antibodies to study functional states and protein interplay.
  • Naveni PD1/PD-L1 target-specific kits Target-specific kits for detecting PD1/PD-L1 interactions in situ with high signal-to-noise ratio. Available in NaveniBright chromogenic (HRP), Atto647N fluorescent, and BOND RX automated versions. First commercial assay for detecting PD1/PD-L1 interaction in situ, used in immunotherapy research and patient stratification studies. Prices range from 18,500 to 29,500 SEK.
  • Naveni CD8/MHC-I kit Target-specific in situ proximity ligation assay kit for detecting CD8/MHC-I interactions, offering novel insights into T-cell engagement and antigen recognition for immune cell dynamics research. Used by Providence Genomics and academic researchers in immunology and immuno-oncology.
  • Naveni BOND RX automated kits Automated proximity ligation assay kits optimized for the Leica BOND RX and RXm Fully Automated Research Stainer, with pre-optimized protocols enabling high-throughput processing. Includes chromogenic (NaveniBright HRP, 29,500 SEK for PD1/PD-L1) and other readout formats designed for immediate application on BOND RX/RXm instruments.
  • Naveni Control Kit Control kit used for validating proximity ligation assay signals when running NaveniFlex and NaveniBright kits. Priced at 3,500 SEK.
  • NaveniLink kit Conjugation kit for creating custom Navenibodies (antibody-oligonucleotide conjugates) with user-provided primary antibodies. Priced at 11,500 SEK, enables researchers to expand the isPLA platform to additional targets of interest.
  • Omni full-service offering Full-service offering for the Omni multiplex kit where Navinci experts perform the experiment on behalf of the customer. Enables researchers without in-house capability to access multiplex spatial interactomics experiments performed by Navinci's scientific team.

Quantifiable outcome

  • 72% year-over-year sales growth in 2025 (86% adjusted for currency)
  • +2 more outcomes

Companies that use Navinci Diagnostics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Navinci Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature8 records

Navinci Diagnostics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and supporting.

  • Uppsala UniversitycoreStrategic or Co-development Partner · 7 April 2026Collaboration as part of the SIXP (Spatial Interactomics with Cell Painting) project to develop next-generation technology platform for mapping cellular signaling and drug responses. Uppsala contributes leading expertise in molecular interaction biology and drug discovery. Joint work includes proof-of-concept studies for Omni technology.
  • SciLifeLabcoreStrategic or Co-development Partner · 7 April 2026Collaboration in the SIXP project providing advanced high content imaging, screening capabilities and data infrastructure. Once established, technology will be implemented within CBCS infrastructure at SciLifeLab enabling national research access.
  • Chemical Biology Consortium Sweden (CBCS)coreStrategic or Co-development Partner · 7 April 2026Part of SIXP collaboration; provides screening infrastructure and will host the technology platform for researcher access across Sweden supporting drug discovery, systems biology, and precision medicine applications.
  • Pixl BiosupportingTechnology or Integration · 7 April 2026Provides advanced image analysis and AI-based tools for spatial data interpretation as part of the SIXP collaboration.
  • Vector LaboratoriescoreStrategic or Co-development Partner · 17 March 2026Joint development of Glysite Explorer kit, integrating Vector's Glysite Explorer lectins with Navinci's proprietary in situ PLA technology for studying protein glycosylation. Won CiteAb Innovation Award 2026. Product adopted by leading research institutions worldwide.
  • Leica BiosystemssupportingTechnology or IntegrationBOND RX/RXm compatibility - Navinci has developed automated proximity ligation assay kits optimized for Leica BOND RX/RXm Fully Automated Research Stainer, enabling high-throughput processing.
  • Harvard Medical School (Barthel and Schatton laboratories)supportingStrategic or Co-development PartnerCollaborative research using Glysite Explorer for studying protein glycosylation in tumor microenvironment; presented findings at NextGen Omics and AACR 2026 conferences.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Navinci Diagnostics competitors and assessment

Company assessment

Emerging players

  • Rebus Biosystems: Emerging U.S. spatial omics company with the STELLARIS platform for highly multiplexed spatial transcriptomics. Competes in the same translational research market but with a narrower technology scope focused on RNA rather than protein-protein interactions.

Others

  • Bio-Techne: Large U.S. life sciences reagents company (including R&D Systems, ProteinSimple, and Advanced Cell Diagnostics) selling antibodies, ELISA kits, and spatial biology reagents. Indirectly comparable as a broad proteomics reagent supplier that researchers may substitute or bundle against Navenci's specialty kits.
  • Vector Laboratories: U.S. immunohistochemistry reagent supplier and Navinci's co-development partner on Glysite Explorer. Adjacent rather than competitive — provides lectin reagents and IHC consumables that Navinci integrates into its isPLA kits.

Broad incumbents

  • Standard BioTools: Former Fluidigm; commercializes the Hyperion imaging mass cytometry platform for highly multiplexed spatial proteomics in tissue. Competes for spatial-proteomics core facility budgets with a broader, more capital-intensive instrument-based offering.
  • 10x Genomics: U.S. leader in single-cell and spatial biology with the Xenium in situ platform (RNA plus emerging protein assays), Visium, and Chromium product lines. Overlaps with Navinci in spatial tissue analysis but addresses a much broader multi-omics portfolio with substantially larger commercial reach.
  • NanoString Technologies (a Bruker company): Spatial biology platforms including CosMx SMI (single-cell spatial molecular imaging) and GeoMx DSP for digital spatial profiling. Larger incumbent with broader spatial transcriptomics and proteomics coverage than Navinci's protein-interaction focus.

Direct peers

  • Olink: Swedish protein biomarker company using Proximity Extension Assay (PEA), a dual-recognition proximity-based technology closely analogous to Navinci's isPLA. Most directly comparable peer by origin (Sweden/Uppsala) and underlying proximity-detection chemistry, though Olink operates in soluble protein biomarkers rather than in situ tissue.
  • Lunaphore: Swiss spatial biology company commercializing the COMET multiplex sequential immunofluorescence platform for tissue proteomics. Directly comparable to Navinci's NaveniFlex/NaveniBright and Omni kits as a competing approach to high-multiplex spatial protein detection in FFPE tissue.
  • Akoya Biosciences: U.S. spatial biology company offering the PhenoCycler (formerly CODEX) platform and OPAL multiplex immunohistochemistry reagents for tissue-based multiplex proteomics. Competes with Navinci for the same translational and academic research budget for spatial protein analysis in tissue.
  • Cell Signaling Technology (CST): Major U.S. antibody and reagent supplier that also markets proximity ligation assay (PLA) kits and IHC reagents. Directly competes with Naveni product lines at the bench-reagent level while also offering the broader antibody portfolio and assay support that researchers often consolidate on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Navinci Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Navinci Diagnostics leadership team

Management profile

Number of profiles

Profiles9 records

Navinci Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Navinci Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Navinci Diagnostics

What does Navinci Diagnostics do?

Navinci develops and commercializes proprietary in situ proximity ligation assay (isPLA) reagent kits for detecting proteins, protein-protein interactions, and post-translational modifications directly within tissue and cell samples, preserving spatial context. The product portfolio includes flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), multiplex kits (Naveni Plex, Omni), and glycosylation detection kits (Glysite Explorer), sold to life science researchers globally.

Is Navinci Diagnostics a public or private company?

Navinci Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Navinci Diagnostics founded?

Navinci Diagnostics was founded in 2004. It employs 11 to 50 people.

Where is Navinci Diagnostics based?

Navinci Diagnostics is headquartered in Uppsala, Sweden, in the Europe region.

How does Navinci Diagnostics make money?

Two revenue lines are on record. Research kits and reagents are the primary driver. The others are custom service offerings.

Who are Navinci Diagnostics's main competitors?

Rebus Biosystems is listed as an emerging player. Others are Bio-Techne and Vector Laboratories. Broad incumbents are Standard BioTools, 10x Genomics and NanoString Technologies (a Bruker company). Direct peers are Olink, Lunaphore, Akoya Biosciences and Cell Signaling Technology (CST).

Does Navinci Diagnostics have an API?

No public API is recorded for Navinci Diagnostics.

What industry is Navinci Diagnostics in?

Navinci Diagnostics's product category is Spatial Proteomics Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comNavinci's Multiplex isPLA, Omni, Featured in Nature Communications Publication from the ASTEROID Phase 1 Clinical TrialNavinci's isPLA technology was used in a Nature Communications publication reporting findings from the ASTEROID Phase 1 trial of tolinapant in advanced solid tumors. The study showed IAP inhibition activates immunogenic cell death and enhances immunotherapy sensitivity, with biomarkers identified for patient selection.news.cision.comNavinci launches NaveniBright™ AUTO for implementation of isPLA on automated staining platformsNavinci launched NaveniBright AUTO, extending its automated isPLA portfolio to open automated staining platforms. The assay generates localized HRP labeling for protein-protein interactions, expression, and PTMs in FFPE tissue, using standard HRP-based detection workflows. It enables researchers to incorporate protein interaction analysis into existing laboratory infrastructure.news.cision.comNavinci technology powers new spatial biomarker approach for predicting immunotherapy responseNavinci's in situ proximity ligation assay detected PD-1/PD-L1 interactions in metastatic urothelial carcinoma, linking them to pembrolizumab response. Interactions involving cytotoxic CD8+ T cells were enriched in complete responders and rare in progressive disease, outperforming PD-L1 expression alone. The preprint suggests a shift toward spatially resolved functional biomarkers.news.cision.comNavinci and BrainZell initiate a collaboration to explore functional spatial biology in human brain organoidsNavinci Diagnostics and BrainZell announced a collaboration to test Navinci's in situ Proximity Ligation Assay in human brain organoids. The feasibility project aims to evaluate functional spatial readouts for drug response studies. Both companies see potential for future CNS research and drug discovery applications.news.cision.comNavinci to host DDLS Industrial Postdoctoral Fellow - Di PengNavinci announced that Dr. Di Peng has been awarded a DDLS Postdoctoral Fellowship 2026, with Navinci as the industrial host. The project uses Navinci's in situ proximity ligation assay technology to study drug resistance in cancer, in collaboration with Dr. Charlotte Stadler at SciLifeLab.news.cision.comNavinci to Showcase Omni at EACR 2026Navinci will showcase its Omni multiplex immunoassay platform at EACR 2026 in Budapest, June 8–11, 2026. The platform uses proprietary isPLA technology for spatial protein analysis, including interactions and post-translational modifications. Researchers can visit booth 27 to learn more.PR Newswirethe next generation of spatial interactomicsSwedish biotech company Navinci announced the launch of Omni, a fully customized spatial interactomics kit that enables scientists to study protein function directly in tissue using proximity ligation assay technology. The product allows simultaneous detection of up to 9 target pairs in a single experiment, revealing protein-protein interactions, post-translational modifications, and single protein targets. In collaboration with Uppsala University, proof-of-concept studies validated the technology's sensitivity and specificity across cell lines and clinical FFPE samples, with Omni now available as both a ready-to-use kit and full-service offering.PR Newswirethe next generation of spatial interactomicsSwedish biotech company Navinci announced the launch of Omni, a fully customized spatial interactomics kit that enables researchers to study protein function directly in tissue using the company's proprietary in situ proximity ligation assay technology. The kit allows simultaneous detection of up to 9 target pairs, including protein-protein interactions and post-translational modifications, within a single experiment. A proof-of-concept study conducted in collaboration with Uppsala University demonstrated the technology's sensitivity and specificity across cell lines and clinical FFPE samples, with the product available as both a ready-to-use kit and a full-service offering.news.cision.comNavinci launches Omni kit – the next generation of spatial interactomicsNavinci launched Omni, fully customized spatial interactomics kits built on its in situ proximity ligation assay technology. The kits detect up to 9 target pairs simultaneously, with pre-validated panels for MAPK signaling, immuno-oncology, and TCR/BCR profiling. A proof-of-concept study with Uppsala University demonstrated high sensitivity and specificity across cell lines and clinical FFPE samples.news.cision.comNavinci Featured in BioStockNavinci, a Swedish biotech company specializing in proximity ligation assay technology for studying protein interactions, was featured in a BioStock article highlighting the company's technology and growth trajectory. CEO Jenny Sundqvist discussed the company's innovative approach to mapping protein interactions in tissue samples and its ongoing investment in multiplexing and spatial biology technologies. The article notes Navinci's consistent double-digit growth and expanding product portfolio.